-
NEWS RELEASE
Wnt/β-catenin in our NASH-HCC model: How does it correlate to human liver cancer?
2021.04.09
The main cause of hepatocellular carcinogenesis today is chronic liver disease following HCV and HBV infection.
-
NEWS RELEASE
2021.04.02
CohBar, Inc. (USA) announced on March 29, 2021, that the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesity.
-
PRODUCTS AND SERVICES
Positive control for UUO kidney fibrosis
2021.03.04
We are excited to share with you an update about a newly established positive control – an ALK5 inhibitor - for our UUO-induced renal fibrosis model.
-
NEWS RELEASE
2021.02.22
Gannex (Shanghai, China) has announced positive clinical results in overweigth and obse subjects for its THR-b agonist ASC41.
-
NEWS RELEASE
2021.02.15
TERNS Pharmaceuticals, Inc. (USA) has announced FDA clearance of investigational new drug aplication for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH.
-
NEWS RELEASE
Inventiva announces design of Phase III clinical trial with Ianifibranor in NASH
2021.02.04
Inventiva (France) has announced design of Phase III clinical trial with Ianifibranor in NASH
-
NEWS RELEASE
2021.01.22
Hepion pharma (NJ), which is our client, has announced positive top line data for low dose CRV431 in Phase 2a "AMBITION" clincal trial for treatment of advanced NASH.
-
NEWS RELEASE
2021.01.14
Lipocine (USA, UA) announced on 12 January, 2021, positive topline Phase 2 results from LPCN1144 ongoing LiFT study in biopsy-confirmed NASH subjects.
-
NEWS RELEASE
Chemomab announces positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients
2021.01.08
Chemomab Ltd.(Israel) announced on 5 January, 2021, positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients.
-
NEWS RELEASE
Can-Fite reports on progress with its Namodenoson NASH program
2020.12.18
Can-Fite (Israel) reports on 14 December, 2020, on progress with its Namodenoson NASH program.
-
NEWS RELEASE
CytoDyn announces first patient enrolled in Phase 2 study for NASH
2020.12.02
CytoDyn (USA, KY) announced on 2 December, 2020, the first patient first visit metric was met for the Phase 2 study for NASH.
-
NEWS RELEASE
Inventiva announces FDA has granted Breakthrough Therapy designation to lanifibranor in NASH
2020.10.21
Inventiva (France) announced on 12 October, 2020, FDA haas granted Breakthrough Therapy designation to lanifibranor for the treatment of NASH.
